Immunomodulation in female B₆C₃F₁ mice following treatment with the HIV protease inhibitor saquinavir for 28 days by gavage

References

• Acosta, E.P., Zorrilla, C., Van Dyke, R., Bardeguez, A., Smith, E., Hughes, M., Huang, S., Pitt, J., Watts, H. and Mofenson, L. Pediatric AIDS Clinical Trials Group 386 Protocol Team. 2001. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin. Trials 2:460–465.
   PubMedGoogle Scholar
• Angel, J.B., Kumar, A., Parato, K., Filion, L.G., Diaz-Mitoma, F., Daftarian, P., Pham, B., Sun, E., Leonard, J.M. and Cameron, D.W. 1998. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J. Infect. Dis. 177:898–904.
   PubMed Web of Science ®Google Scholar
• Autar, R.S., Boffito, M., Hassink, E., Wit, F.W., Ananworanich, J., Siangphoe, U., Pozniak, A., Cooper, D.A., Phanuphak, P., Lange, J.M., Ruxrungtham, K. and Burger, D.M. 2005. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J. Antimicrob. Chemother. 56:908–913.
   PubMed Web of Science ®Google Scholar
• Auttachoat, W., Germolec, D.R., Collins, B.J., Luebke, R.W., White, K.L. Jr and Guo, T.L. 2009. Immunotoxicological profile of chloroform in female B6C3F1 mice when administered in drinking water. Drug Chem. Toxicol. 32:77–87.
   PubMed Web of Science ®Google Scholar
• Binley, J.M., Trkola, A., Ketas, T., Schiller, D., Clas, B., Little, S., Richman, D., Hurley, A., Markowitz, M. and Moore, J.P. 2000. The effect of highly active anti-retroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus Type 1 infection. J. Infect. Dis. 182:945–949.
   PubMedGoogle Scholar
• Bucy, R.P., Hockett, R.D., Derdeyn, C.A., Saag, M.S., Squires, K., Sillers, M., Mitsuyasu, R.T. and Kilby, J.M. 1999. Initial increase in blood CD4(+) lymphocytes after HIV anti-retroviral therapy reflects redistribution from lymphoid tissues. J. Clin. Invest. 103:1391–1398.
   PubMed Web of Science ®Google Scholar
• Chêne, G., Binquet, C., Moreau, J.F., Neau, D., Pellegrin, I., Malvy, D., Ceccaldi, J., Lacoste, D. and Dabis, F. 1998. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active anti-retroviral treatment. Groupe d’Epidémiologie Clinique du SIDA en Aquitaine. AIDS 12:2313–2320.
   PubMedGoogle Scholar
• Comandini, F.A., Lombardi, A., Saponiero, A. and Bonmassar, E. 2001. Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3/CD28. J. Chemother. 13:384–388.
   PubMedGoogle Scholar
• Eagling, V.A., Back, D.J. and Barry, M.G. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol. 44:190–194.
   PubMed Web of Science ®Google Scholar
• Ernest, C.S. 2nd, Hall, S.D. and Jones, D.R. 2005. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 312:583–591.
   PubMed Web of Science ®Google Scholar
• Franzese, O., Lombardi, A., Comandini, A., Cannavò, E., Testorelli, C., Cirello, I. and Bonmassar, E. 2001. Effect of Saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells. Life Sci. 69:1509–1520.
   PubMedGoogle Scholar
• Germolec, D.R., Maronpot, R.R., Ackermann, M.F., Vore, S.J., Dittrich, K., Rosenthal, G.J. and Luster, M.I. 1988. Lack of a relationship between immune function and chemically induced hepatocarcinogenesis in B6C3F1 mice. Cancer Immunol. Immunother. 27:121–127.
   PubMed Web of Science ®Google Scholar
• Gruber, A., Wheat, J.C., Kuhen, K.L., Looney, D.J. and Wong-Staal, F. 2001. Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. J. Biol. Chem. 276:47840–47843.
   PubMedGoogle Scholar
• Grundy, M.A., Zhang, T. and Sentman, C.L. 2007. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. Cancer Immunol. Immunother. 56:1153–1161.
   PubMed Web of Science ®Google Scholar
• Gupta, A.K., Cerniglia, G.J., Mick, R., McKenna, W.G. and Muschel, R.J. 2005. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. 65:8256–8265.
   PubMed Web of Science ®Google Scholar
• Hogg, R.S., O’Shaughnessy, M.V., Gataric, N., Yip, B., Craib, K., Schechter, M.T. and Montaner, J.S. 1997. Decline in deaths from AIDS due to new anti-retroviral. Lancet 349:1294.
   PubMed Web of Science ®Google Scholar
• Hsu, A., Granneman, G.R., Cao, G., Carothers, L., el-Shourbagy, T., Baroldi, P., Erdman, K., Brown, F., Sun, E. and Leonard, J.M. 1998. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin. Pharmacol. Ther. 63:453–464.
   PubMed Web of Science ®Google Scholar
• Jerne, N.K. and Nordin, A.A. 1963. Plaque formation in agar by single antibody-producing cells. Science 140:405.
   Web of Science ®Google Scholar
• Knysz, B., Zalewska, M., Rzeszutko, M. and Gladysz, A. 2006. Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART. Postepy. Hig. Med. Dosw. (Online). 60:181–183.
   PubMedGoogle Scholar
• Lai, S., Lai, H., Celentano, D.D., Vlahov, D., Ren, S., Margolick, J., Lima, J.A. and Bartlett, J.G. 2003. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. AIDS Patient Care STDS 17:211–219.
   PubMedGoogle Scholar
• Lu, W. and Andrieu, J.M. 2000. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: A viral-suppression-independent mechanism. Blood 96:250–258.
   PubMed Web of Science ®Google Scholar
• Matarrese, P., Gambardella, L., Cassone, A., Vella, S., Cauda, R. and Malorni, W. 2003. Mitochondrial membrane hyperpolarization hijacks activated T-lymphocytes toward the apoptotic-prone phenotype: Homeostatic mechanisms of HIV protease inhibitors. J. Immunol. 170:6006–6015.
   PubMedGoogle Scholar
• Mildvan, D., Creagh, T. and Leitz, G.; Anemia Prevalence Study Group. 2007. Prevalence of anemia and correlation with biomarkers and specific anti-retroviral regimens in 9690 human-immunodeficiency-virus-infected patients: Findings of the Anemia Prevalence Study. Curr. Med. Res. Opin. 23:343–355.
   PubMed Web of Science ®Google Scholar
• Murray, M.J., Kerkvliet, N.I., Ward, E.C., and Dean, J.H. 1985. Models for the evaluation of tumor resistance following chemical or drug exposure. In: Immunotoxicology and Immunopharmacology (Dean, J.H., Luster, M.I., Munson, A.E., and Amos, H., Eds.), New York: Raven Press, pp. 113–122.
   Google Scholar
• Needham, D.M., Hogg, R.S., Yip, B., O’Shaughnessy, M., Schechter, M.T. and Montaner, J.S. 1998. The impact of anti-retroviral therapy on AIDS survival observed in a province-wide drug treatment programme. Int. J. STD AIDS 9:370–372.
   PubMedGoogle Scholar
• Pacifici, R., Di Carlo, S., Bacosi, A., Pichini, S. and Zuccaro, P. 1997. Cytokine production in saquinavir treated mice. Int. J. Immunopharmacol. 19:243–248.
   PubMed Web of Science ®Google Scholar
• Pajonk, F., Himmelsbach, J., Riess, K., Sommer, A. and McBride, W.H. 2002. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 62:5230–5235.
   PubMed Web of Science ®Google Scholar
• Parhar, R.S. and Lala, P.K. 1987. Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2. J. Exp. Med. 165:14–28.
   PubMed Web of Science ®Google Scholar
• Perry, C.M. and Noble, S. 1998. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection Drugs 55:461–486.
   PubMed Web of Science ®Google Scholar
• Reynolds, C.W. and Herberman, R.B. 1981. In vitro augmentation of rat natural killer (NK) cell activity. J. Immunol. 126:1581–1585.
   PubMed Web of Science ®Google Scholar
• Sarmati, L., Nicastri, E., el-Sawaf, G., Ventura, L., Salanitro, A., Ercoli, L., Vella, S. and Andreoni, M. 1997. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment. J. Med. Virol. 53:313–318.
   PubMedGoogle Scholar
• Schapiro, J.M., Kamel, O.W., Winters, M.A., Vierra, M., Efron, B., and Merigan, T.C. 1997. Lymph node histopathology in HIV-infected patients correlates with duration of response to anti-retroviral therapy. Conf. Retrovir. Oppor. Infect. 4th 1997, Washington DC. Jan 22-26; 4th:164 (Abstract #538).
   Google Scholar
• Schütt, M., Zhou, J., Meier, M. and Klein, H.H. 2004. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J. Endocrinol. 183:445–454.
   PubMed Web of Science ®Google Scholar
• Sgadari, C., Monini, P., Barillari, G. and Ensoli, B. 2003. Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumour growth. Lancet Oncol. 4:537–547.
   PubMed Web of Science ®Google Scholar
• Sparano, J.A., Wiernik, P.H., Hu, X., Sarta, C., Henry, D.H. and Ratech, H. 1998. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma. Med. Oncol. 15:50–57.
   PubMed Web of Science ®Google Scholar
• Viora, M., Di Genova, G., Quaranta, M.G., Boirivant, M. and Camponeschi, B. 1998. Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC. J. Clin. Immunol. 18:346–354.
   PubMed Web of Science ®Google Scholar
• von Hentig, N., Förster, A.K., Kuczka, K., Klinkhardt, U., Klauke, S., Gute, P., Staszewski, S., Harder, S. and Graff, J. 2008. Platelet-leucocyte adhesion markers before and after the initiation of anti-retroviral therapy with HIV protease inhibitors. J. Antimicrob. Chemother. 62:1118–1121.
   PubMedGoogle Scholar
• Washington, C.B., Wiltshire, H.R., Man, M., Moy, T., Harris, S.R., Worth, E., Weigl, P., Liang, Z., Hall, D., Marriott, L. and Blaschke, T.F. 2000. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab. Dispos. 28:1058–1062.
   PubMed Web of Science ®Google Scholar
• Winston, A., Mallon, P.W., Satchell, C., MacRae, K., Williams, K.M., Schutz, M., Law, M., Cooper, D.A. and Emery, S. 2007. The safety, efficacy, and pharmacokinetic profile of a switch in anti-retroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clin. Infect. Dis. 44:1475–1483.
   PubMed Web of Science ®Google Scholar
• Zorrilla, C.D., Van Dyke, R., Bardeguez, A., Acosta, E.P., Smith, B., Hughes, M.D., Huang, S., Watts, D.H., Heckman, B., Jiménez, E., McSherry, G. and Mofenson, L. 2007. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus Type 1-infected mothers and their infants. Antimicrob. Agents Chemother. 51:2208–2210.
   PubMed Web of Science ®Google Scholar